Noom GLP-1 Review: Noom Med and Weight Loss Options

Noom Med is a legitimate prescription weight-loss program from a well-known digital health company, and its real difference from other GLP-1 telehealth services is the behavior-change app wrapped around the medication. As of October 2026 it offers a long menu: brand-name GLP-1s, generic medications, and Noom's own compounded GLP-1 programs, which are made by pharmacies and are not FDA-approved. Knowing which of those you are signing up for is the most important step.

• Noom, Inc. launched in 2008 as a weight-loss app built on psychology-based lessons. Geoff Cook is its CEO.
• Noom Med, its prescription program, launched in May 2023 after a pilot in 2022.
• In October 2026, Noom's Med page listed brand-name GLP-1s from Novo Nordisk and Eli Lilly, generic liraglutide and metformin, alongside Noom-branded GLP-1Rx programs.
• Noom's own "GLP-1 Access and Transparency" page says it prescribes generic, compounded and brand-name medications. Compounded medications are not FDA-approved.
• In April 2026, Noom bought Tailor Made Compounding, a licensed 503A compounding pharmacy based in Kentucky. Compounded medications are not FDA-approved.
• Insurance is not required, but Noom says it will help members who have insurance try to get medication covered.

Disclosure: Rx.com runs its own GLP-1 weight-loss program, so Noom is a competitor. This review is based on Noom's own website and press materials, news coverage, court-related reporting and published customer reviews, all linked below.

What Noom and Noom Med Are

Noom is a digital health company widely known for its weight-loss app, which uses psychology-based lessons, food logging and coaching to change eating habits. It launched in 2008, and its CEO is Geoff Cook. For most of its history Noom did not prescribe anything; members used the app and worked with coaches.

That changed in May 2023, when Noom launched Noom Med after a pilot the previous year. At launch it was available in 32 states, and it offered prescription medications alongside the behavior program, with an initial video visit and text-based follow-up with clinicians. Noom has expanded the program steadily since, adding its own compounded GLP-1 program (compounded drugs are not FDA-approved) in September 2024, a "microdose" program in 2025, and, in April 2026, a compounding pharmacy of its own.

Noom's pitch is that medication alone is not enough. On its site, Noom says it treats GLP-1s "not as a band-aid, but as a bridge," and that its goal is to help members build habits that last, including after they stop the medication. In 2026 Noom published several analyses of its own members and announced results from a randomized clinical trial of its program, and in August 2026 it launched a campaign with actor Rebel Wilson arguing that medication and healthy habits work better together.

How the Noom Weight Loss Program Works

Based on Noom's Med page and its transparency page as of October 2026, the process looks like this:

1. Intake survey. You share your health history and goals online. Noom says it verifies every patient's identity, requires a full-body photo before treatment and requires a comprehensive medical intake.
2. Clinician review. A licensed clinician evaluates your answers and, if clinically appropriate, prescribes online. Noom says its care is mainly asynchronous (by message), with video visits available in some programs.
3. Medication. If prescribed, medication is shipped to you or coordinated through your own pharmacy. Noom notes that not all medications are available for home delivery, depending on whether you use insurance or pay cash.
4. Ongoing care. Noom says members get unlimited access to their clinician and refills where clinically appropriate, plus "SmartDose" titration (gradual, personalized dosing) and side effect management.
5. The app. All medication plans include the Noom app, which Noom calls its GLP-1 Companion: lessons, tracking, a 1:1 coach, a community and a "Muscle Defense" program aimed at preserving muscle while losing weight.

In May 2026, Noom also announced an at-home biomarkers test kit, which it says lets members see how their health markers change over time.

What Noom Med Prescribes

Noom Med's menu is broader than most GLP-1 programs, and it mixes FDA-approved products with Noom's own compounded programs, which are not FDA-approved. We have split them into two groups below so it is clear which is which.

FDA-approved and generic medications on Noom's list

When we checked Noom's Med page in October 2026, it listed these products:

Ozempic and Mounjaro are FDA-approved for type 2 diabetes rather than weight loss. Noom's FAQ says brand-name medications are available when appropriate and that your out-of-pocket cost for them depends on your insurance coverage. One Noom Med member's review in October 2026 described paying Noom for the program and paying NovoCare, Novo Nordisk's pharmacy, separately for the medication, so ask how your specific prescription will be filled and billed.

Noom's own GLP-1Rx programs

Noom's page also lists four Noom-branded programs: Noom GLP-1Rx, Noom Microdose GLP-1Rx, Noom GLP-1Rx Plus and Noom Microdose GLP-1Rx Plus. According to news coverage of their launches, Noom GLP-1Rx (September 2024) and Noom's microdose program (May 2025) are compounded semaglutide programs, which are not FDA-approved; at launch, Noom said GLP-1Rx was made by an FDA-regulated 503B compounding pharmacy. The main Med page does not state the active ingredient in the "Plus" programs, so ask before you enroll.

Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they reach patients. Noom says the pharmacies it works with for these programs are state-regulated and follow U.S. Pharmacopeia (USP) standards, that they source active ingredients from suppliers on the FDA's "green list," that every batch is tested by a third-party lab, and that members can request a Certificate of Analysis from the care team.

In April 2026 Noom completed its purchase of Tailor Made Compounding, a 503A pharmacy headquartered in Kentucky that operates in 46 states. Noom said the pharmacy would run as a wholly owned subsidiary. If you are on a compounded program (compounded drugs are not FDA-approved), it is reasonable to ask which pharmacy fills your prescription and whether that could change.

Noom's Microdose Approach

"Microdose" is Noom's term for starting at a low dose and increasing slowly. Noom describes its dosing philosophy as "low and slow," with three tiers it calls microdose, standard and maintenance, and says it aims for the least medication needed for meaningful results for each member. When Noom introduced the microdose program in 2025, reporting described it as starting low and stepping up gradually over about 20 weeks.

A slower start can make side effects such as nausea easier to manage, which is one reason many prescribers titrate gradually. Keep in mind that the evidence Noom cites for low-dose results comes largely from its own member data, which is self-reported and not the same as a randomized trial. Talk with your clinician about what dose makes sense for your goals and health history, and do not expect a low dose to work the same way for everyone.

Is Noom Med Legit?

Yes. Noom is an established company with licensed clinicians, published research and a large member base, and Noom Med has operated since 2023. Here is the public record worth knowing as of October 2026:

• Clinical leadership. Noom names Dr. Jeffrey Egler, a double board-certified family and lifestyle medicine physician, as its chief medical officer, and lists a medical director and pharmacy and clinical advisors on its transparency page.
• Research. Noom announced in June 2026 that its largest randomized clinical trial found members kept losing weight a year after the program ended, and separately published analyses of members who stopped GLP-1s. These are Noom's own announcements.
• 2022 subscription settlement. In 2022, Noom settled a federal class action in New York that alleged its free trials led to auto-renewals that were hard to cancel. Under the settlement, Noom agreed to change its practices, including clearer auto-renewal disclosures, a separate step to accept auto-renewal, and a cancellation button on the account page.
• FDA. Our search of the FDA's posted warning letters did not turn up one addressed to Noom. That reflects our search as of October 2026, not a guarantee.
• BBB. Noom, Inc. is BBB-accredited. Its BBB complaints page notes that, because of high complaint volume, BBB publishes one of every five complaints handled through its process. Noom responds to complaints there, and in several recent cases it issued refunds.

What Noom Med Reviews Say

We read recent reviews on Trustpilot (filtered for GLP-1 comments) and the BBB in October 2026. Most of Noom's Trustpilot reviews are about the app rather than Noom Med, and Trustpilot notes Noom has not invited customers to review recently. These are self-selected comments, not a survey.

What people like

• The app and lessons. Reviewers consistently praise the psychology-based lessons, meal tracking and the way the program keeps them accountable.
• Supportive clinicians and coaches. Several GLP-1 reviewers say their clinicians and care team made them feel safe starting medication for the first time and checked in regularly.
• The low-dose start. Some members on the microdose program say it worked well for them with few side effects.
• Easy to stop. At least one recent reviewer specifically noted that unsubscribing was easy, without pressure to continue.

What people complain about

• Charges and renewals. BBB complaints often describe a low first charge followed by a much larger renewal the reviewer says they did not expect, or charges for add-on products they did not want.
• Refunds after shipping. Some complainants were told refunds were not possible once medication had shipped, including one who said they were told they were not a candidate after the order had been processed.
• Prescription coordination. Some members on brand-name medication describe delays getting a prescription sent to the outside pharmacy, and having to chase it themselves.
• Pharmacy changes. A BBB complaint in September 2026 described being moved to a different pharmacy mid-treatment.

What Affects the Cost of Noom Med

We do not list prices here. Noom publishes its current pricing on noom.com, and it varies by program. What drives the cost:

• Which program you choose. Noom's compounded GLP-1Rx programs (which are not FDA-approved) and its brand-name track are priced differently. Noom's FAQ says the microdose program's pricing applies regardless of insurance.
• Brand-name medication is billed separately. For brand-name drugs, Noom's FAQ describes a program fee plus your out-of-pocket cost for the medication itself, which depends on your insurance.
• Introductory pricing. Noom advertises a lower starting price for some programs. Check what the second month and later months cost before you enroll.
• Insurance. Insurance is not required. Noom says it will work to maximize coverage for members who have it and offers a GLP-1 insurance checker.
• FSA and HSA. Noom marks several programs as FSA/HSA eligible, while noting that every plan is different.

Pros and Cons of Noom Med

Pros

• Behavior-change app, coaching and lessons included with every medication plan
• Wide choice, including brand-name, generic and low-dose options
• Identity verification and a detailed intake before prescribing
• Insurance support for members who have coverage
• Published clinical leadership and its own research program

Cons

• The mix of programs makes it easy to be unsure which medication you are getting
• Brand-name track adds a program fee on top of medication
• Recurring complaints about renewal charges and refunds after shipping
• Care is mostly by message, with video only in some programs
• A 2022 class-action settlement over its earlier subscription practices

Alternatives to Noom for GLP-1 Weight Loss

Rx.com's GLP-1 program

Rx.com runs its own online weight-loss program with an online visit with a licensed U.S. provider. The price is the same at every dose, no insurance is needed, medication ships to your door, and you are not charged for medication if you are not approved. Rx.com is LegitScript certified. See if Rx.com's GLP-1 program is right for you.

Your own doctor and your insurance

Your primary care doctor or an obesity specialist can prescribe an FDA-approved GLP-1 and handle prior authorization. You can still use a habit-building app on your own if the behavior side is what appeals to you about Noom.

The manufacturers' self-pay pharmacies

Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare Pharmacy) sell their brand-name GLP-1s directly to self-pay patients with a valid prescription. If you already have a prescriber, this can remove a program fee.

Other telehealth GLP-1 programs

Ro and Hims also run GLP-1 programs. Ro emphasizes insurance help, and Hims offers a wide menu of brand-name products with a membership. See our Ro weight loss review and Hims weight loss review.

How Rx.com Differs

Rx.com's program is built around a simple question: will you qualify, and what will it cost, before you pay for medication. You start with an online visit with a licensed U.S. provider. If you are approved, your medication ships to your door. If you are not approved, you are not charged for medication. You do not need insurance.

Rx.com prescribes compounded semaglutide and compounded tirzepatide at the same price at every dose, so increasing your dose does not raise your bill. Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality. Rx.com is LegitScript certified.

The fair comparison: if a guided habit program is what you want most, Noom's app is its strength. If you want a straightforward prescription program with one steady price, Rx.com is worth comparing.